Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients?
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 24
- Locations
- 1
- Primary Endpoint
- Evolution of Drug representation in Patients : Verbal association
Study Overview
Brief Summary
Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management. This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group.
Detailed Description
Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management.
The therapeutic educational program ETPARK includes individual's consults or workshop. The team frequently offer to patients to participate in workshop on Parkinson disease's drug.
This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group (speaking group) at 1 and 3 months.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with Parkinson's disease according to the United Kingdom Parkinson Disease Society Brain Bank (UKPDSBB) criteria,
- •Patients who are already in therapeutic education program ETPARK,
- •Patients who need and want to participate in therapeutic education workshop on Parkinson disease drug,
- •Patients with health insurance,
- •Patients who have signed a written informed consent form.
Exclusion Criteria
- •Patients suffering from another parkinsonian syndrome (multiple system atrophy, progressive supranuclear palsy etc.),
- •Patients who has already done workshop on Parkinson disease drug (program ETPARK)
- •Patients already included in clinical trial during the study,
- •Patients who have severe psychiatric disorders or dopaminergic psychosis,
- •Patients with cognitive impairment,
- •Patients unable to complete the various scales used in the study,
- •Patients under juridical protection,
- •Women pregnant or breastfeeding.
Arms & Interventions
Therapeutic education workshop
Two group receive therapeutic education workshop already existing in Toulouse University Hospital
Intervention: Therapeutic education workshop (Other)
Speaking Therapy
One group receive speaking therapy already existing in Toulouse University Hospital
Intervention: Speaking Therapy (Other)
Outcomes
Primary Outcomes
Evolution of Drug representation in Patients : Verbal association
Time Frame: Three months
Evolution of Drug representation through verbal association tasks compared to the control group. Evolution will be compared between the Baseline and the end of the study
Evolution of Drug representation in Patients : BMQ
Time Frame: Three months
Evolution of Drug representation through the Believe about Medicines Questionnaire (BMQ) compared to the control group. Evolution will be compared between the Baseline and the end of the study BMQ with eighteen items coded from 1 " "strongly agree" to 5 "strongly disagree".
Secondary Outcomes
- Drug representation in caregivers : Verbal association(Day 1)
- Drug representation in caregivers : BMQ(Day 1)
- Evolution in life quality : PDQ-(39)(three months)
- Knowledge about the disease(three months)
- Evolution in life quality : VAS(three months)